Fig. 28

(Abstract P23). Anti-HER2 primary human CARMA were tested in immunodeficient mouse models of human HER2+ ovarian cancer (schema, a). CARMA but not control untransduced macrophages reduced tumor burden (b, c) and prolonged survival by 30 days (p=0.018, d)